On June 16, 2025, Verve Therapeutics, Inc. agreed to merge with Eli Lilly and Company, involving a cash offer of $10.50 per share plus contingent rights potentially totaling $3.00 per share, with a total value depending on specified milestones.
AI Assistant
VERVE THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.